PURPOSE: We investigate radio-labeling and pharmacokinetics of a new AnnexinA5 variant (HYNIC-cys-AnxA5) and then assess its utility for the non-invasive detection of cell death in liver, spleen and prostate. METHODS: AnnexinA5 binds to phosphatidylserine expressed on the surface of apoptotic and necrotic cells. Contrary to other AnnexinA5 variants, the new cys-AnxA5 allows for site-specific conjugation of a hydrazinonicotinamide-maleimide moiety and subsequent radio-labeling with (99m)Tc at a position not involved in the AnxA5-phosphatidylserine interaction. Distribution of (99m)Tc-HYNIC-cys-AnxA5 was studied in rats, both invasively and via SPECT/CT. Cycloheximide was used to induce cell death in liver and spleen, whereas apoptosis in the prostate was induced by castration. RESULTS: HYNIC-cys-AnxA5 was efficiently and reproducibly labeled with (99m)Tc. Blood clearance of radioactivity after iv-injection was adequately described by a two-compartment model, the renal cortex representing the main site of accumulation. Cycloheximide treatment resulted in increased accumulation of intravenous-injected (99m)Tc-HYNIC-cys-AnxA5 in liver and spleen over controls, which correlated well with TUNEL staining for cell death in corresponding tissue sections. However, the increase in TUNEL-positive prostate epithelial cells observed following castration was not paralleled by greater (99m)Tc-HYNIC-cys-AnxA5 accumulation. CONCLUSION: (99m)Tc-HYNIC-cys-AnxA5 appears a suitable tracer for assessment of cell death in liver and spleen, but not prostate.
PURPOSE: We investigate radio-labeling and pharmacokinetics of a new AnnexinA5 variant (HYNIC-cys-AnxA5) and then assess its utility for the non-invasive detection of cell death in liver, spleen and prostate. METHODS:AnnexinA5 binds to phosphatidylserine expressed on the surface of apoptotic and necrotic cells. Contrary to other AnnexinA5 variants, the new cys-AnxA5 allows for site-specific conjugation of a hydrazinonicotinamide-maleimide moiety and subsequent radio-labeling with (99m)Tc at a position not involved in the AnxA5-phosphatidylserine interaction. Distribution of (99m)Tc-HYNIC-cys-AnxA5 was studied in rats, both invasively and via SPECT/CT. Cycloheximide was used to induce cell death in liver and spleen, whereas apoptosis in the prostate was induced by castration. RESULTS:HYNIC-cys-AnxA5 was efficiently and reproducibly labeled with (99m)Tc. Blood clearance of radioactivity after iv-injection was adequately described by a two-compartment model, the renal cortex representing the main site of accumulation. Cycloheximide treatment resulted in increased accumulation of intravenous-injected (99m)Tc-HYNIC-cys-AnxA5 in liver and spleen over controls, which correlated well with TUNEL staining for cell death in corresponding tissue sections. However, the increase in TUNEL-positive prostate epithelial cells observed following castration was not paralleled by greater (99m)Tc-HYNIC-cys-AnxA5 accumulation. CONCLUSION:(99m)Tc-HYNIC-cys-AnxA5 appears a suitable tracer for assessment of cell death in liver and spleen, but not prostate.
Authors: R F Haverdings; M Haas; A R Greupink; P A de Vries; F Moolenaar; D de Zeeuw; D K Meijer Journal: Ren Fail Date: 2001 May-Jul Impact factor: 2.606
Authors: Hendrikus H Boersma; Bas L J H Kietselaer; Leo M L Stolk; Abdelkader Bennaghmouch; Leonard Hofstra; Jagat Narula; Guido A K Heidendal; Chris P M Reutelingsperger Journal: J Nucl Med Date: 2005-12 Impact factor: 10.057
Authors: Klaus Kopka; Andreas Faust; Petra Keul; Stefan Wagner; Hans-Jörg Breyholz; Carsten Höltke; Otmar Schober; Michael Schäfers; Bodo Levkau Journal: J Med Chem Date: 2006-11-16 Impact factor: 7.446
Authors: Rick Greupink; Catharina Reker-Smit; Johannes H Proost; Anne-miek van Loenen Weemaes; Marjolijn de Hooge; Klaas Poelstra; Leonie Beljaars Journal: Biochem Pharmacol Date: 2006-12-15 Impact factor: 5.858
Authors: H H Boersma; I H Liem; G J Kemerink; P W L Thimister; L Hofstra; L M L Stolk; W L van Heerde; M-T W Pakbiers; D Janssen; A J Beysens; C P M Reutelingsperger; G A K Heidendal Journal: Br J Radiol Date: 2003-08 Impact factor: 3.039
Authors: L J Rijks; J C van den Bos; P A van Doremalen; G J Boer; K de Bruin; T Doornbos; J A Vekemans; M A Posthumus; A G Janssen; E A van Royen Journal: Nucl Med Biol Date: 1998-05 Impact factor: 2.408
Authors: Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde Journal: Med Res Rev Date: 2018-03-12 Impact factor: 12.944